Zentalis Pharmaceuticals, Inc.
ZNTL$67M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO166 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Dec 1, 2026
32wMarket Overview
Stock performance and key metrics
ZNTL News
Catalyst Timeline
1 upcoming, 1 past
Drug Pipeline
ZN-d5
Amyloidosis
Niraparib
Ovarian Cancer
azenosertib
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
ZN-c3
Uterine Serous Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ZN-d5 | Phase 2 | Amyloidosis | - | - |
Niraparib | Phase 2 | Ovarian Cancer | - | - |
azenosertib | Phase 2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | - | - |
ZN-c3 | Phase 2 | Uterine Serous Carcinoma | - | - |
Amyloidosis
1 drug in this indication
Ovarian Cancer
1 drug in this indication
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
1 drug in this indication
Uterine Serous Carcinoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply